Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah‐Eddin Al‐Batran, Andrea Tannapfel, Sylvie Lorenzen et al.|The Lancet Oncology|2016Cited by 738
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction CancerSalah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Nils Homann et al.|JAMA Oncology|2017Cited by 473
Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagusUlrich Ronellenfitsch, Matthias Schwarzbach, Ralf‐Dieter Hofheinz et al.|Cochrane Database of Systematic Reviews|2013Cited by 178
Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate dataUlrich Ronellenfitsch, Katrin Jensen, Matthias Schwarzbach et al.|European Journal of Cancer|2013Cited by 169